Tuesday, November 24, 2009, 3:53AM AEST - The Australian Stockmarket opens in 6 hours and 7 minutes.
To create a watchlist or portfolio of shares, Register

Achillion Pharmaceuticals, Inc. (ACHN)

On Nov 21: 1.92 USD   0.00 (0.00%)  
 MORE ON ACHN 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Achillion Pharmaceuticals, Inc. (NGM:ACHN) Delayed quote dataEdit
Last Trade:1.92 USD
Trade Time:Nov 21
Change: 0.00 (0.00%)
Prev Close:1.92
Open:1.90
Bid:1.87 x 100
Ask:1.99 x 400
1y Target Est:4.50
Day's Range:N/A - N/A
52wk Range:0.65 - 2.42
Volume:0
Avg Vol (3m):32,351.5
Market Cap:51.18M
P/E (ttm):N/A
EPS (ttm):-1.05
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add ACHN to Portfolio   Download Data

 HEADLINES 
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
EDGAR Online (Wed, Nov 18)
Achillion Receives Notice From NASDAQ
GlobeNewswire (Wed, Nov 18)
New Star Analyst Rankings for Achillion Pharmaceuticals, Inc.
StarMine (Wed, Nov 11)
Morningstar Strategist Says Healthcare Bill Will Be Law By End Of Year: Is Your Portfolio Ready?
Wall Street Transcript (Tue, Nov 10)
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
EDGAR Online (Sat, Nov 7)
Achillion Reports Third Quarter Results
GlobeNewswire (Fri, Nov 6)
Achillion to Present at Three Upcoming Conferences
GlobeNewswire (Fri, Oct 30)
Coverage initiated on Achillion Pharma by Wedbush Morgan
Briefing.com (Thu, Oct 22)
Achillion Completes Phase 1a Trial of ACH-1625; Begins Dosing in Phase 1b Segment With HCV-Infected Patients
GlobeNewswire (Mon, Sep 28)
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Fri, Sep 4)
More Headlines for ACHN...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.94
EPS Est (in 2 years) (Dec-10) :-0.62
Avg Rec (current)*:2.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices